Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Income towards Parent Company (2019 - 2025)

Eton Pharmaceuticals' Income towards Parent Company history spans 7 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Income towards Parent Company fell 407.34% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$6.7 million, down 21.91%, while the annual FY2024 figure was -$3.8 million, 308.44% down from the prior year.
  • Income towards Parent Company for Q3 2025 was -$1.9 million at Eton Pharmaceuticals, up from -$2.6 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $5.1 million in Q1 2021 and bottomed at -$6.1 million in Q3 2021.
  • The 5-year median for Income towards Parent Company is -$1.6 million (2025), against an average of -$1.1 million.
  • The largest annual shift saw Income towards Parent Company surged 392.62% in 2023 before it plummeted 407.34% in 2025.
  • A 5-year view of Income towards Parent Company shows it stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then tumbled by 347.37% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then crashed by 222.24% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Income towards Parent Company are -$1.9 million (Q3 2025), -$2.6 million (Q2 2025), and -$1.6 million (Q1 2025).